JOIN THE BATTLE. Beat Rare Cancers.
Our dream is a world without cancer.
We're participating in Cycle for Survival in honor of our sister, daughter and friend, Jenn Brandi.
Diagnosed with clear cell carcinoma at age 18, she was the epitome of a rare case. When doctors at Dana Farber Cancer Institute couldn't treat her aggressive tumor, she relocated to New York City to seek care at Memorial Sloan Kettering. With the expertise and extraordinary care of the doctors, nurses, and truly everyone at MSK, Jenn battled through. After a three year fight, she was declared cancer free.
August 2019 marked her 9th year in remission.
We ride for Jenn, for all survivors, for those still battling, and for those who have lost their fight. Every dollar raised through Cycle for Survival supports rare cancer research at Memorial Sloan Kettering. Additionally, Jenn's doctor directly benefits from this funding - something that means the world to us.
We appreciate your support as we do our part in moving this important work forward. A donation of any size makes a difference.
THANK YOU for your support - we are so thankful.
Team Spinday Scaries
50% of People with Cancer Have a Rare Cancer
Did you know that, when combined, about half of all patients fighting cancer are fighting a rare cancer? These are cancers you’ve likely heard of — such as leukemia, lymphoma, thyroid, ovarian, brain, pancreatic, and all pediatric cancers.
100% of Your Donation Supports Research
Every dollar you give funds innovative studies and clinical trials led by Memorial Sloan Kettering Cancer Center (MSK). Discoveries made by MSK revolutionize how cancer is diagnosed and treated, helping patients everywhere.
6 Months for Fast Impact
Rare cancer research is underfunded, and too often people don’t have proven treatments. Time matters. Your gift will be in the hands of researchers six months after fundraising ends and, as a donor, you will learn about the projects supported.
If you think this page contains objectionable content, please inform the system administrator.